Affiliation: | aDepartment of Pharmacology/Toxicology and Medicine, Virginia Commonwealth University, Medical College of Virginia, P.O. Box 980230, Richmond, VA 23298, USA bJohn Wayne Cancer Institute, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA cDepartment of Biostatistics, Virginia Commonwealth University, Medical College of Virginia, P.O. Box 980030, Richmond, VA 23298, USA dDepartments of Tumor Biology and Oncology, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway |
Abstract: | A senescence-like growth arrest succeeded by recovery of proliferative capacity was observed in MCF-7 breast tumor cells exposed to fractionated radiation, 5 × 2 Gy. Exposure to EB 1089, an analog of the steroid hormone 1, 25 dihydroxycholecalciferol (1, 25 dihydroxy Vitamin D3; calcitriol), prior to irradiation promoted cell death and delayed both the development of a senescent phenotype and the recovery of proliferative capacity. EB 1089 also reduced clonogenic survival over and above that produced by fractionated radiation alone and further conferred susceptibility to apoptosis in MCF-7 cells exposed to radiation. In contrast, EB 1089 failed to enhance the response to radiation (or to promote apoptosis) in normal breast epithelial cells or BJ fibroblast cells. EB 1089 treatment and fractionated radiation additively promoted ceramide generation and suppressed expression of polo-like kinase 1. Taken together, these data indicate that EB 1089 (and 1, 25 dihydroxycholecalciferol or its analogs) could selectively enhance breast tumor cell sensitivity to radiation through the promotion of cell death, in part through the generation of ceramide and the suppression of polo-like kinase. |